Interstitial lung disease (ILD) is a frequent organ manifestation in systemic sclerosis (SSc) and is associated with high morbidity and mortality.1 The severity and disease course vary widely from mild and stable disease to severe and rapidly progressing.2 Early detection of ILD and prediction of disease progression are key in the management of SSc-ILD, as any ILD in SSc is associated with reduced long-term outcome especially in case of disease progression.1 There has been substantial progress in the treatment of this devastating condition, but allocation of the right treatment at the right time for any given individual with SSc-ILD remains challenging. While several risk factors for ILD progression in SSc have been identified in the past, the predictive ability of single factors is very moderate.3 Combination of different risk factors such as early disease, increased inflammatory markers, recent skin progression and the diffuse cutaneous SSc subset have been shown to improve the identification of patients at risk of progression.3 However, a high unmet need still exists to specifically identify the individual patient with SSc-ILD who is at risk of progressive disease, to initiate treatment early, to prevent progression and to avoid irreversible …

中文翻译：

---

更接近于解决预测系统性硬化症相关间质性肺疾病疾病进展的谜团？

间质性肺病 (ILD) 是系统性硬化症 (SSc) 中常见的器官表现，并且与高发病率和死亡率相关。1 严重程度和病程差异很大，从轻度稳定的疾病到严重且快速进展的疾病。2 早期发现 ILD和预测疾病进展是 SSc-ILD 管理的关键，因为 SSc 中的任何 ILD 都与长期预后降低有关，尤其是在疾病进展的情况下。 1 在治疗这种破坏性疾病方面取得了实质性进展，但在正确的时间为任何特定的 SSc-ILD 个体分配正确的治疗仍然具有挑战性。虽然过去已经确定了 SSc 中 ILD 进展的几个风险因素，但单个因素的预测能力非常中等。